For the quarter ended December 2022, Thermo Fisher Scientific (TMO - Free Report) reported revenue of $11.45 billion, up 7% over the same period last year. EPS came in at $5.40, compared to $6.54 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $10.36 billion, representing a surprise of +10.55%. The company delivered an EPS surprise of +4.05%, with the consensus EPS estimate being $5.19.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Thermo Fisher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Organic Growth: -3% versus the four-analyst average estimate of -11.2%.
- Revenues-Life Sciences Solutions: $3.05 billion versus the six-analyst average estimate of $2.76 billion. The reported number represents a year-over-year change of -26.6%.
- Revenue-Analytical Instruments: $1.88 billion versus $1.66 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change.
- Revenue-Eliminations: -$536 million versus -$717.17 million estimated by six analysts on average.
- Revenue-Laboratory Products and Biopharma Services: $5.95 billion compared to the $5.55 billion average estimate based on six analysts. The reported number represents a change of +41.8% year over year.
- Revenue-Specialty Diagnostics: $1.12 billion versus $1.09 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -22.9% change.
- Operating income-Life Sciences Solutions: $1.04 billion compared to the $1.12 billion average estimate based on three analysts.
- Operating income-Laboratory Products and Biopharma Services: $836 million versus $694.79 million estimated by three analysts on average.
- Operating Income-Specialty Diagnostics: $208 million versus the three-analyst average estimate of $220.02 million.
- Operating income-Analytical Instruments: $476 million compared to the $397.11 million average estimate based on three analysts.
View all Key Company Metrics for Thermo Fisher here>>>
Shares of Thermo Fisher have returned +3.1% over the past month versus the Zacks S&P 500 composite's +6.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For the quarter ended December 2022, Thermo Fisher Scientific (TMO - Free Report) reported revenue of $11.45 billion, up 7% over the same period last year. EPS came in at $5.40, compared to $6.54 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $10.36 billion, representing a surprise of +10.55%. The company delivered an EPS surprise of +4.05%, with the consensus EPS estimate being $5.19.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Thermo Fisher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
View all Key Company Metrics for Thermo Fisher here>>>
Shares of Thermo Fisher have returned +3.1% over the past month versus the Zacks S&P 500 composite's +6.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on TMO - FREE